A part of Watch Media

MedWatchSaturday4 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
25/07/2022at 10:57

Needham lifts Bavarian Nordic's target stock price 13%

Asset manager Needham boosted the target share price of the Danish vaccine maker on Friday.
Photo: Philip Davali/Ekstra Bladet, Philip Davali
by marketwire, translated by jonas sahl hollænder

The target share price for Bavarian Nordic was increased by 13% to DKK 370 (USD 50.7) from DKK 327 (USD 44.81) by asset manager Needham, according to data compiled by Bloomberg News.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Sven Hoppe/AP/Ritzau Scanpix

    Bavarian Nordic expects imminent European monkeypox green light

    For subscribers

  • Photo: Mike Blake/Reuters/Ritzau Scanpix

    CHMP gives Eli Lilly diabetes drug the nod

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Nu mangler kun en endelig vedtagelse i EU-Parlamentet, før lovforslag om at udskyde deadlines for nye krav til medicinsk udstyr. er en realitet. | Foto: Thomas Borberg/Ritzau Scanpix
Medtech

Another hurdle overcome in delaying MDR deadline

EU member countries have voted unanimously to adopt an EU Commission proposal to stagger the implementation of the new Medical Device Regulation. Now, only the EU Parliament’s vote remains. 
  • Asensus Surgical wins CE Mark for intelligent surgical unit under MDR rules
  • EU Commission to give more time for MDR transition

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk hopes to retain employees with share gift

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

Luja can potentially solve a long-lived UTI problem for people who need help with bladder control issues by using new micro-hole technology
Medtech

Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps

For subscribers

Foto: Coloplast/pr
Medtech

Coloplast launches male catheter featuring new technology

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast's bottom line disappoints in otherwise strong report

For subscribers

Further reading

Photo: Gn Hearing / Pr
Hearing health

GN's high expectations deadlocking stock price

Despite shorting positions declining the past month, the hearing company’s equity hasn’t moved an inch in 2023 – perhaps due to conflicting expectations for a yet-to-be-revealed fourth-quarter report.

For subscribers

Photo: Euha/foto Rechnitz
Hearing health

New batch of hearing firm recommendations moves GN up, Demant and Sonova down

Jefferies takes stock of hearing aid industry, and comes up with a new string of recommendations.

For subscribers

Photo: Pr/gn
Hearing health

GN could be potential acquisition target, says bank

Danske Bank’s share price target for GN Group leaves a lot stock potential.

For subscribers

Latest news

  • Top news from MedWatch this week – 3 Feb
  • Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps – 3 Feb
  • China accepts regulatory filing for ALK allergy tablet – 3 Feb
  • Another hurdle overcome in delaying MDR deadline – 3 Feb
  • Dupixent becomes ninefold blockbuster – 3 Feb
  • ALK forecasts lower growth in 2023 than strong 2022 result – 3 Feb
  • Unilabs and Siemens Healthineers enter million-euro strategic partnership – 3 Feb
  • Coloplast launches male catheter featuring new technology – 3 Feb
  • Novo Nordisk hopes to retain employees with share gift – 3 Feb
  • Coloplast's bottom line disappoints in otherwise strong report – 3 Feb
See all

Jobs

  • Senior Clinical Project Manager

  • Medical Advisor (Metabolism)

  • Experienced Patent Counsel

  • Application Manager

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Sr. Director, Drug Safety Physician

  • Commercial Director

  • Supply Chain Manager

  • Clinical Operational Associate

  • Lead Data Architect

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Regulatory Affairs Professional

See all jobs

Jobs

  • Senior Clinical Project Manager

  • Medical Advisor (Metabolism)

  • Experienced Patent Counsel

  • Application Manager

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Sr. Director, Drug Safety Physician

  • Commercial Director

  • Supply Chain Manager

  • Clinical Operational Associate

  • Lead Data Architect

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Regulatory Affairs Professional

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge